Novel Transcatheter Left Atrial Appendage Exclusion with the Laminar Device: Preclinical and Early First-in-Human Clinical Results

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Abbott
• Equity/Stock(s)/Options - Laminar